The Korea Economic TV | Reporter Yang Jae-joon, IT·Bio Department
Published date : August 2nd, 2022
Bioplus announced on the 2nd that it participated in the Florida International Medical Expo (FIME) held at the Miami Convention Center from July 27 to 29 and introduced various next-generation bio products.
“FIME” is the largest medical device exhibition in the Americas, including the United States, Canada, Brazil, and Latin America, with 12,000 medical staff and industry officials from 120 countries around the world participating every year.
Bioplus introduced improved Light-Chain botulinum toxin that improved efficacy and half-life by introducing peptides, as well as improved obesity/diabetes treatments developed into biobetter technology through protein half-life control and GLP-1 (Glucagon Peptide Receptor-1) manufacturing technology.
A company official said, “Through this FIME participation, we have established a bridgehead to enter the American market and established a strategic network. In particular, we will focus on expanding new countries through aggressive sales and marketing targeting Latin America.”